Radiation and immunotherapy combinations in non-small cell lung cancer

Soheila Azghadi, Megan E. Daly

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. The recent development of immune checkpoint inhibitors has afforded a durable, dramatic treatment response for a subset of patients, but strategies to expand these benefits to a broader swath of patients are needed. Preliminary evidence suggests radiotherapy may modulate a patient's immune system, particularly when delivered in high doses over few fractions with conformal techniques, as with stereotactic ablative radiotherapy (SABR). Radiotherapy for advanced stage NSCLC has traditionally been administered with palliative intent. However, an emergence of data from retrospective studies and, more recently, prospective trials has indicated the potential of using stereotactic ablative radiotherapy (SABR), in combination with systemic immunotherapy agents have synergistic effect and may enhance survival. We review current evidence for synergy between radiation and immunotherapy in metastatic, locally advanced, and localized NSCLC and discuss ongoing studies.

Original languageEnglish (US)
Article number100298
JournalCancer Treatment and Research Communications
StatePublished - Jan 2021


  • Immunotherapy
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Radiation and immunotherapy combinations in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this